See, in our law, "new form of a known substance" is not patentable unless it significantly improves therapeutic efficacy. The Glivec judgment stood firm on this, stopping Novartis from evergreening by patenting a salt form of imatinib. That judgment is a pillar for affordable generics. In my research, I've seen patients' files shift from despair to hope when Glivec's price dropped after the generics came—that data is my life's proof.
#athletics#track-and-field
Jump in to reply — no account needed.